@article{SchlickeweiNienstedtFranketal.2021,
  author    = {Schlickewei, Ole and Nienstedt, Julie Cl{\"a}re and Frank, Ulrike and Fr{\"u}ndt, Odette and P{\"o}tter-Nerger, Monika and Gerloff, Christian and Buhmann, Carsten and M{\"u}ller, Frank and Lezius, Susanne and Koseki, Jana-Christiane and Pflug, Christina},
  title     = {The ability of the eating assessment tool‑10 to detect penetration and aspiration in Parkinson's disease},
  series = {European archives of oto-rhino-laryngology and head \& neck},
  volume    = {278},
  journal   = {European archives of oto-rhino-laryngology and head \& neck},
  number    = {5},
  publisher = {Springer},
  address   = {Berlin},
  issn      = {0937-4477},
  doi       = {10.1007/s00405-020-06377-x},
  pages     = {1661 -- 1668},
  year      = {2021},
  abstract  = {Purpose: Dysphagia is common in patients with Parkinson's disease (PD) and often leads to pneumonia, malnutrition, and reduced quality of life. This study investigates the ability of the Eating Assessment Tool-10 (EAT-10), an established, easy self-administered screening tool, to detect aspiration in PD patients. This study aims to validate the ability of the EAT-10 to detect FEES-proven aspiration in patients with PD. Methods: In a controlled prospective cross-sectional study, a total of 50 PD patients completed the EAT-10 and, subsequently, were examined by Flexible Endoscopic Evaluation of Swallowing (FEES) to determine the swallowing status. The results were rated through the Penetration-Aspiration Scale (PAS) and data were analyzed retrospectively. Results: PAS and EAT-10 did not correlate significantly. Selected items of the EAT-10 could not predict aspiration or residues. 19 (38\%) out of 50 patients with either penetration or aspiration were not detected by the EAT-10. The diagnostic accuracy was established at only a sufficient level (AUC 0.65). An optimal cut-off value of >= 6 presented a sensitivity of 58\% and specificity of 82\%. Conclusions: The EAT-10 is not suited for the detection of penetration and aspiration in PD patients. Therefore, it cannot be used as a screening method in this patient population. There is still a need for a valid, simple, and efficient screening tool to assist physicians in their daily diagnostics and to avoid clinical complications.},
  language  = {en}
}
@article{HortobagyiGranacherFernandezdelOlmoetal.2020,
  author    = {Hortobagyi, Tibor and Granacher, Urs and Fernandez-del-Olmo, Miguel and Howatson, Glyn and Manca, Andrea and Deriu, Franca and Taube, Wolfgang and Gruber, Markus and Marquez, Gonzalo and Lundbye-Jensen, Jesper and Colomer-Poveda, David},
  title     = {Functional relevance of resistance training-induced neuroplasticity in health and disease},
  series = {Neuroscience \& biobehavioral reviews : official journal of the International Behavioral Neuroscience Society},
  volume    = {122},
  journal   = {Neuroscience \& biobehavioral reviews : official journal of the International Behavioral Neuroscience Society},
  publisher = {Elsevier},
  address   = {Oxford},
  issn      = {0149-7634},
  doi       = {10.1016/j.neubiorev.2020.12.019},
  pages     = {79 -- 91},
  year      = {2020},
  abstract  = {Repetitive, monotonic, and effortful voluntary muscle contractions performed for just a few weeks, i.e., resistance training, can substantially increase maximal voluntary force in the practiced task and can also increase gross motor performance. The increase in motor performance is often accompanied by neuroplastic adaptations in the central nervous system. While historical data assigned functional relevance to such adaptations induced by resistance training, this claim has not yet been systematically and critically examined in the context of motor performance across the lifespan in health and disease. A review of muscle activation, brain and peripheral nerve stimulation, and imaging data revealed that increases in motor performance and neuroplasticity tend to be uncoupled, making a mechanistic link between neuroplasticity and motor performance inconclusive. We recommend new approaches, including causal mediation analytical and hypothesis-driven models to substantiate the functional relevance of resistance training-induced neuroplasticity in the improvements of gross motor function across the lifespan in health and disease.},
  language  = {en}
}
@phdthesis{Stoessel2018,
  author    = {St{\"o}ßel, Daniel},
  title     = {Biomarker Discovery in Multiple Sclerosis and Parkinson's disease},
  school      = {Universit{\"a}t Potsdam},
  pages     = {135},
  year      = {2018},
  abstract  = {Neuroinflammatory and neurodegenerative diseases such as Parkinson's (PD) and multiple sclerosis (MS) often result in a severe impairment of the patient´s quality of life. Effective therapies for the treatment are currently not available, which results in a high socio-economic burden. Due to the heterogeneity of the disease subtypes, stratification is particularly difficult in the early phase of the disease and is mainly based on clinical parameters such as neurophysiological tests and central nervous imaging. Due to good accessibility and stability, blood and cerebrospinal fluid metabolite markers could serve as surrogates for neurodegenerative processes. This can lead to an improved mechanistic understanding of these diseases and further be used as "treatment response" biomarkers in preclinical and clinical development programs. Therefore, plasma and CSF metabolite profiles will be identified that allow differentiation of PD from healthy controls, association of PD with dementia (PDD) and differentiation of PD subtypes such as akinetic rigid and tremor dominant PD patients. In addition, plasma metabolites for the diagnosis of primary progressive MS (PPMS) should be investigated and tested for their specificity to relapsing-remitting MS (RRMS) and their development during PPMS progression. By applying untargeted high-resolution metabolomics of PD patient samples and in using random forest and partial least square machine learning algorithms, this study identified 20 plasma metabolites and 14 CSF metabolite biomarkers. These differentiate against healthy individuals with an AUC of 0.8 and 0.9 in PD, respectively. We also identify ten PDD specific serum metabolites, which differentiate against healthy individuals and PD patients without dementia with an AUC of 1.0, respectively. Furthermore, 23 akinetic-rigid specific plasma markers were identified, which differentiate against tremor-dominant PD patients with an AUC of 0.94 and against healthy individuals with an AUC of 0.98. These findings also suggest more severe disease pathology in the akinetic-rigid PD than in tremor dominant PD. In the analysis of MS patient samples a partial least square analysis yielded predictive models for the classification of PPMS and resulted in 20 PPMS specific metabolites. In another MS study unknown changes in human metabolism were identified after administration of the multiple sclerosis drug dimethylfumarate, which is used for the treatment of RRMS. These results allow to describe and understand the hitherto completely unknown mechanism of action of this new drug and to use these findings for the further development of new drugs and targets against RRMS. In conclusion, these results have the potential for improved diagnosis of these diseases and improvement of mechanistic understandings, as multiple deregulated pathways were identified. Moreover, novel Dimethylfumarate targets can be used to aid drug development and treatment efficiency. Overall, metabolite profiling in combination with machine learning identified as a promising approach for biomarker discovery and mode of action elucidation.},
  language  = {en}
}